Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Blood

• Publication date

  2017-04-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2016-10-747345PMID 28167659PMCID PMC5399483
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The bendamustine plus rituximab regimen is active against primary nodal marginal zone B‐cell lymphoma

  2017cited by this paper
• Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

  2016cited by this paper
• Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

  2016cited by this paper
• Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

  2015influential reference
• Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

  2015cited by this paper
• Inhibitors of BCR signalling interrupt the survival signal mediated by the micro‐environment in mantle cell lymphoma

  2015cited by this paper
• Non‐Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011

  2015cited by this paper
• Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)

  2014influential reference
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014cited by this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014influential reference
• Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

  2014influential reference
• A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)

  2013influential reference
• Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.

  2013cited by this paper
• B-cell receptor signaling as a driver of lymphoma development and evolution.

  2013cited by this paper
• ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

  2013cited by this paper
• Survival of patients with marginal zone lymphoma

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

  2013influential reference
• Ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Ibrutinib in relapsed chronic lymphocytic leukemia.

  2013influential reference
• Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

  2013influential reference
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

  2013cited by this paper
• BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas

  2012cited by this paper
• The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

  2012cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

  2012cited by this paper
• Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).

  2011cited by this paper
• Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).

  2010cited by this paper
• 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.

  2010cited by this paper
• Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma

  2009cited by this paper
• A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

  2009cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma

  2007cited by this paper
• Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation.

  2006cited by this paper
• Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.

  2003cited by this paper
• Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.

  2002cited by this paper
• The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis.

  2001cited by this paper
• Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

  2000influential reference
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

  1997cited by this paper
• A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project

  1997cited by this paper
• Helicobacter pylori infection and gastric lymphoma.

  1994cited by this paper

• Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.

  2026cites this paper
• Marginal zone lymphoma presenting with chylous ascites: A rare clinical manifestation and successful treatment with orelabrutinib–rituximab

  2026cites this paper
• Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies.

  2026cites this paper
• Speed and Nature of National Comprehensive Cancer Network Updates Following Food and Drug Administration Approvals & Withdrawals.

  2026cites this paper
• Bruton’s Tyrosine Kinase: A Potential Novel Target for Neurological Disorders

  2025cites this paper
• Loss of CYLD promotes splenic marginal zone lymphoma

  2025cites this paper
• Exploring causal relationship between 41 inflammatory cytokines and marginal zone lymphoma: A bidirectional Mendelian randomization study

  2025cites this paper
• Configurational and Conformational Proclivity of an α-Cyanoacrylamide Derivative of Ibrutinib.

  2025cites this paper
• Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States

  2025influential citation
• A Durable Remission Following Pseudo‐Progression in Tirabrutinib Treatment for Relapsed Primary Central Nervous System Lymphoma: A Case Study

  2025cites this paper
• SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma.

  2025cites this paper
• SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone Lymphoma.

  2025cites this paper
• Clinical and imaging features of primary thyroid MALT lymphoma

  2025cites this paper
• The Treatment of Marginal Zone Lymphoma.

  2025cites this paper
• BCL‐2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma

  2025cites this paper
• Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma

  2025cites this paper
• Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma

  2025cites this paper
• Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2

  2025cites this paper
• Drug development in MZL: caring for the forgotten child.

  2025cites this paper
• Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma

  2025cites this paper
• Recent developments in marginal zone lymphoma

  2024cites this paper
• Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma

  2024influential citation
• Extranodal marginal zone lymphoma of the larynx: A case report and scoping review

  2024cites this paper
• B-cell non-Hodgkin lymphomas.

  2024cites this paper
• Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

  2024cites this paper
• Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma

  2024cites this paper
• Recent Advancement in Drug Designing as Small Molecules in Targeted Cancer Therapy: Challenges and Future Directions.

  2024cites this paper
• Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

  2024cites this paper
• A marginális zóna lymphoma korszerű diagnosztikája és kezelése

  2024cites this paper
• Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

  2024cites this paper
• Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies

  2024cites this paper
• Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia

  2023cites this paper
• What is new about primary cutaneous B cell lymphomas.

  2023cites this paper
• Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy.

  2023cites this paper
• Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

  2023cites this paper
• Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label study

  2023influential citation
• Zanubrutinib: past, present, and future

  2023cites this paper
• A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

  2023cites this paper
• Retrospective characterization of nodal marginal zone lymphoma

  2023cites this paper
• Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline

  2023cites this paper
• Marginal zone lymphoma: 2023 update on diagnosis and management

  2023cites this paper
• A new prognostic nomogram in patients with mucosa-associated lymphoid tissue lymphoma: a multicenter retrospective study

  2023influential citation
• Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2

  2023cites this paper
• Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies

  2023cites this paper
• Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis

  2023cites this paper
• Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma

  2023cites this paper
• Serositis causing pericardial and pleural effusions after eight years of maintenance ibrutinib for Waldenstrom's macroglobulinemia.

  2023cites this paper
• Lymphomes de la zone marginale

  2023cites this paper
• Extranodal lymphoma: pathogenesis, diagnosis and treatment

  2023cites this paper
• – inHaematology SPECIAL ISSUE

  2023cites this paper
• Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review

  2023cites this paper
• Urinary tract infection following the use of BTK inhibitors: a real-world analysis of post-marketing surveillance data

  2023cites this paper
• B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells

  2023cites this paper
• Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis

  2023cites this paper
• Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal

  2023cites this paper
• China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022)

  2023cites this paper
• Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus‐based position paper from an ad hoc expert panel

  2023cites this paper
• Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors

  2023cites this paper
• Receptors of immune cells mediates recognition for tumors.

  2023cites this paper
• Incidence of Pneumocystis jirovecii pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis

  2022cites this paper
• Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

  2022cites this paper
• Novel treatments in B cell non-Hodgkin’s lymphomas

  2022cites this paper
• The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma

  2022cites this paper
• Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

  2022cites this paper
• Ibrutinib-associated Dermatologic Toxicities: A Systematic Review and Meta-analysis.

  2022cites this paper
• Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study

  2022cites this paper
• A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia

  2022cites this paper
• Ibrutinib-Associated Life-Threatening Hemorrhage with Subcapsular Renal Hematoma and Hemothorax

  2022cites this paper
• Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma

  2022cites this paper
• Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials

  2022cites this paper
• Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders

  2022influential citation
• Postibrutinib relapse outcomes for patients with marginal zone lymphoma

  2022cites this paper
• Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study

  2022cites this paper
• Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

  2022cites this paper
• BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

  2022cites this paper
• Marginal zone lymphoma: present status and future perspectives

  2022cites this paper
• Management of marginal zone lymphomas.

  2022cites this paper
• A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

  2022cites this paper
• Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study

  2022cites this paper
• Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

  2022cites this paper
• The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review

  2022cites this paper
• Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma

  2022influential citation
• Current and Future Therapies for Marginal Zone Lymphoma

  2022cites this paper
• Zanubrutinib for the Treatment of B-cell Malignancies

  2022cites this paper
• Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First

  2022cites this paper
• Small molecule inhibitors targeting the cancers

  2022cites this paper
• Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

  2022cites this paper
• [Splenic lymphoma, diagnosis and treatment].

  2022cites this paper
• Pyrazolopyrimidines as attractive pharmacophores in efficient drug design: A recent update

  2022cites this paper
• Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V2) Therapy

  2022cites this paper
• Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.

  2022cites this paper
• Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma

  2022cites this paper
• Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial

  2022cites this paper
• Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives

  2022cites this paper
• Zanubrutinib in lymphoproliferative disorders: a comprehensive review

  2022cites this paper
• Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.

  2021cites this paper
• Nodal Marginal Zone Lymphoma

  2021cites this paper
• Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)

  2021cites this paper
• Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma

  2021cites this paper
• Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms

  2021cites this paper